
Please try another search
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 for the treatment of herpes simplex virus-1 oncolytic virus C134. The company was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
Name | Age | Since | Title |
---|---|---|---|
Manuel Litchman | 71 | 2017 | President, CEO, Interim CFO & Director |
Michael S. Weiss | 59 | 2015 | Executive Chairman |
Neil Herskowitz | 68 | 2015 | Independent & Non-Executive Director |
Lindsay Allan Rosenwald | 70 | 2015 | Non-Executive Director |
Michael J. Zelefsky | 65 | 2017 | Independent Director |
Adam J. Chill | 57 | 2017 | Independent Director |
David Jin | 34 | 2024 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review